Charles Schwab Investment Management Inc Biomarin Pharmaceutical Inc Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,423,508 shares of BMRN stock, worth $92.3 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,423,508
Previous 1,401,628
1.56%
Holding current value
$92.3 Million
Previous $98.5 Million
5.03%
% of portfolio
0.02%
Previous 0.02%
Shares
30 transactions
Others Institutions Holding BMRN
# of Institutions
635Shares Held
183MCall Options Held
2.07MPut Options Held
1.72M-
Black Rock Inc. New York, NY22.7MShares$1.47 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.4MShares$1.26 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.2MShares$1.18 Billion0.94% of portfolio
-
Dodge & Cox San Francisco, CA14.7MShares$956 Million0.61% of portfolio
-
Capital Research Global Investors Los Angeles, CA13MShares$843 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.1B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...